An immune checkpoint molecule, SA-4-1BB developed for cancer immunotherapy also protects against future development of multiple types of cancer when administered by itself, shows a new study.

The recombinant protein molecule SA-4-1BBL has been used to enhance the therapeutic efficacy of cancer vaccines with success in pre-clinical animal models.